search
Back to results

Prospective Paired Study on the Effectiveness of MitoGrade

Primary Purpose

Infertility

Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
MitoGrade
Sponsored by
Reprogenetics
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Infertility focused on measuring Preimplantation Genetic Screening

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

Center criteria:

1. Offered only to those clinics with >20% MitoGrade elevated embryos

Patient criteria:

  1. Persons undergoing IVF and Preimplantation genetic screening (PGS) through Next Generation Sequencing (NGS) will be eligible to be a part of the study.
  2. The study will be limited to those patients who have 4 or more PGS-classified normal embryos
  3. Patients not undergoing PGS will not be included as part of the study.
  4. Patients undergoing PGD (for genetic disorders) plus PGS will be excluded.

Exclusion Criteria:

1. No other specific group of individuals (age, ethnicity, egg donation, etc) will be excluded.

Sites / Locations

  • ReprogeneticsRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Double embryo transfer

Arm Description

Patients with both MitoGrade normal and Mitograde elevated PGS normal embryos will have two embryos replaced- one Mitograde normal and one Mitograde elevated.

Outcomes

Primary Outcome Measures

Implantation rates between MitoGrade normal and MitoGrade elevated embryos
Using DNA fingerprinting (via cheek swab) to determine which embryo implanted

Secondary Outcome Measures

Full Information

First Posted
February 1, 2016
Last Updated
March 14, 2016
Sponsor
Reprogenetics
search

1. Study Identification

Unique Protocol Identification Number
NCT02673125
Brief Title
Prospective Paired Study on the Effectiveness of MitoGrade
Official Title
Prospective Paired Study on the Effectiveness of MitoGrade
Study Type
Interventional

2. Study Status

Record Verification Date
March 2016
Overall Recruitment Status
Unknown status
Study Start Date
December 2015 (undefined)
Primary Completion Date
December 2016 (Anticipated)
Study Completion Date
January 2017 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Reprogenetics

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Chromosomal abnormalities are a major cause of pregnancy loss. Preimplantation Genetic Screening (PGS) using Next Generation Sequencing (NGS) allows the effective detection of these abnormalities and improves clinical outcomes. However even the transfer of a chromosomally normal embryo does not guarantee successful implantation. Recent research by Fragouli, et. al. 2015 has demonstrated a strong association between mitochondrial DNA quantities (also known as MitoGradeTM) and implantation outcomes in embryos that are already classified by PGS as chromosomally normal. Investigators have also demonstrated in a clinical study that MitoGradeTM normal and PGS normal embryos have higher chances of implantation than MitoGrade elevated PGS normal embryos. Transferring MitoGrade elevated PGS normal embryos results in less than 10% implantation rates while MitoGrade normal PGS normal embryos resulted in more than 65% implantation rates. The risk of miscarriage after replacing either type is very low (about 8%). In order to understand the complete effectiveness of the test, investigators are conducting a paired prospective study. This means that investigators will be transferring a MitoGrade normal and a MitoGrade elevated embryo at the same time to see if one implants better than the other. It is expected that patients joining this study will benefit from knowing that at least one embryo is MitoGrade normal PGS normal.
Detailed Description
Mitochondria are considered the powerhouses of cells. These membrane-bound organelles play a vital role in embryonic development and are essential for various cellular functions. And unlike other cellular organelles, they contain their own DNA (also known as mitochondrial DNA or mtDNA). Embryonic development is a complex energy-driven process and is thought to be highly dependent on mitochondrial function and mtDNA gene expression. It is believed that amounts of mtDNA remain constant in first three days of preimplantation development. Significant alterations in mtDNA are not initiated until after day 5 when the embryo has undergone the first cellular differentiation into trophectoderm (TE) and inner cell mass. It is possible that mtDNA variation may account chromosomal abnormalities by affecting the accuracy of chromosome segregation. In addition to describing the relationship between mtDNA expression and clinical outcomes, Reprogenetics and Fragouli et al. (2015) were able to establish a threshold over which no clinical pregnancy was established. These results were further validated in a prospective blinded study and independently validated using Next Generation Sequencing (NGS) analysis. The quantification of mtDNA therefore provides important information in selecting the best embryos for transfer. MitoGradeTM is a real-time polymerase chain reaction (PCR) based method developed to quantify the amount of mitochondrial DNA (mtDNA) present in human preimplantation embryos. It is believed that a chromosomally normal embryo with a MitoGradeTM score lower than the established threshold will have a higher chance of successful implantation in comparison to a similar embryo with a higher MitoGradeTM score.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infertility
Keywords
Preimplantation Genetic Screening

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Double embryo transfer
Arm Type
Experimental
Arm Description
Patients with both MitoGrade normal and Mitograde elevated PGS normal embryos will have two embryos replaced- one Mitograde normal and one Mitograde elevated.
Intervention Type
Genetic
Intervention Name(s)
MitoGrade
Intervention Description
MitoGrade refers to the mitochondrial DNA assessment in embryos.
Primary Outcome Measure Information:
Title
Implantation rates between MitoGrade normal and MitoGrade elevated embryos
Description
Using DNA fingerprinting (via cheek swab) to determine which embryo implanted
Time Frame
Post natal analysis (9-10 months after replacement)

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Center criteria: 1. Offered only to those clinics with >20% MitoGrade elevated embryos Patient criteria: Persons undergoing IVF and Preimplantation genetic screening (PGS) through Next Generation Sequencing (NGS) will be eligible to be a part of the study. The study will be limited to those patients who have 4 or more PGS-classified normal embryos Patients not undergoing PGS will not be included as part of the study. Patients undergoing PGD (for genetic disorders) plus PGS will be excluded. Exclusion Criteria: 1. No other specific group of individuals (age, ethnicity, egg donation, etc) will be excluded.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Krithika Ravichandran, MSc
Phone
973-436-5000
Email
research@reprogenetics.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Santiago Munne, PhD
Organizational Affiliation
Reprogenetics
Official's Role
Study Director
Facility Information:
Facility Name
Reprogenetics
City
Livingston
State/Province
New Jersey
ZIP/Postal Code
07039
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
973-436-5000
Email
research@reprogenetics.com
First Name & Middle Initial & Last Name & Degree
Santiago Munne, Ph.D

12. IPD Sharing Statement

Citations:
PubMed Identifier
26039092
Citation
Fragouli E, Spath K, Alfarawati S, Kaper F, Craig A, Michel CE, Kokocinski F, Cohen J, Munne S, Wells D. Altered levels of mitochondrial DNA are associated with female age, aneuploidy, and provide an independent measure of embryonic implantation potential. PLoS Genet. 2015 Jun 3;11(6):e1005241. doi: 10.1371/journal.pgen.1005241. eCollection 2015 Jun.
Results Reference
result

Learn more about this trial

Prospective Paired Study on the Effectiveness of MitoGrade

We'll reach out to this number within 24 hrs